Ergomed logo

ERGO - Ergomed News Story

685p -5.0  -0.7%

Last Trade - 10:20am

Sector
Healthcare
Size
Small Cap
Market Cap £334.0m
Enterprise Value £325.2m
Revenue £68.3m
Position in Universe 625th / 1807

Ergomed plc - Block listing application

Wed 27th June, 2018 11:52am
RNS Number : 7744S
Ergomed plc
27 June 2018
 

PRESS RELEASE

FOR IMMEDIATE RELEASE

 

 

Block listing application

 

London, UK - 27 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 1,800,000 ordinary shares of £0.01 each (the 'New Ordinary Shares') to be admitted to trading on AIM.

 

The New Ordinary Shares will be issued from time to time in order to satisfy the exercise of share options granted under the Ergomed plc Share Incentive Plan. It is expected that admission will become effective on 2 July 2018.

 

When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of £0.01 each in the capital of the Company ('Ordinary Shares').

 

The Company will notify as required when there are changes to the issued share capital of the Company, and these figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

ENDS

 

Enquiries:

 

Ergomed plc

   Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)


James Black (Joint Broker)




N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott / Ivar Milligan




MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKMGZVGNGGRZM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.